Janux Therapeutics Statistics
Total Valuation
JANX has a market cap or net worth of $1.40 billion. The enterprise value is $422.16 million.
Important Dates
The next estimated earnings date is Wednesday, November 5, 2025, after market close.
| Earnings Date | Nov 5, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
JANX has 60.09 million shares outstanding. The number of shares has increased by 20.02% in one year.
| Current Share Class | 60.09M |
| Shares Outstanding | 60.09M |
| Shares Change (YoY) | +20.02% |
| Shares Change (QoQ) | +0.18% |
| Owned by Insiders (%) | 6.55% |
| Owned by Institutions (%) | 92.46% |
| Float | 44.97M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3,179.91 |
| Forward PS | 480.68 |
| PB Ratio | 1.39 |
| P/TBV Ratio | 1.41 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 961.64 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 47.03, with a Debt / Equity ratio of 0.02.
| Current Ratio | 47.03 |
| Quick Ratio | 46.85 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -12.82% and return on invested capital (ROIC) is -10.69%.
| Return on Equity (ROE) | -12.82% |
| Return on Assets (ROA) | -10.51% |
| Return on Invested Capital (ROIC) | -10.69% |
| Return on Capital Employed (ROCE) | -14.33% |
| Revenue Per Employee | $5,420 |
| Profits Per Employee | -$1.30M |
| Employee Count | 81 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -51.49% in the last 52 weeks. The beta is 2.84, so JANX's price volatility has been higher than the market average.
| Beta (5Y) | 2.84 |
| 52-Week Price Change | -51.49% |
| 50-Day Moving Average | 24.15 |
| 200-Day Moving Average | 31.67 |
| Relative Strength Index (RSI) | 47.56 |
| Average Volume (20 Days) | 714,565 |
Short Selling Information
The latest short interest is 8.30 million, so 13.81% of the outstanding shares have been sold short.
| Short Interest | 8.30M |
| Short Previous Month | 8.05M |
| Short % of Shares Out | 13.81% |
| Short % of Float | 18.46% |
| Short Ratio (days to cover) | 13.08 |
Income Statement
In the last 12 months, JANX had revenue of $439,000 and -$105.64 million in losses. Loss per share was -$1.80.
| Revenue | 439,000 |
| Gross Profit | -67.95M |
| Operating Income | -144.88M |
| Pretax Income | -105.64M |
| Net Income | -105.64M |
| EBITDA | -142.80M |
| EBIT | -144.88M |
| Loss Per Share | -$1.80 |
Full Income StatementBalance Sheet
The company has $996.01 million in cash and $22.19 million in debt, giving a net cash position of $973.82 million or $16.20 per share.
| Cash & Cash Equivalents | 996.01M |
| Total Debt | 22.19M |
| Net Cash | 973.82M |
| Net Cash Per Share | $16.20 |
| Equity (Book Value) | 990.52M |
| Book Value Per Share | 16.70 |
| Working Capital | 984.17M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$59.79 million and capital expenditures -$911,000, giving a free cash flow of -$60.70 million.
| Operating Cash Flow | -59.79M |
| Capital Expenditures | -911,000 |
| Free Cash Flow | -60.70M |
| FCF Per Share | -$1.01 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -33,002.05% |
| Pretax Margin | -24,064.01% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
JANX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -20.02% |
| Shareholder Yield | -20.02% |
| Earnings Yield | -7.57% |
| FCF Yield | -4.35% |
Analyst Forecast
The average price target for JANX is $76.55, which is 229.53% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $76.55 |
| Price Target Difference | 229.53% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (5Y) | 92.92% |
| EPS Growth Forecast (5Y) | 0.22% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
JANX has an Altman Z-Score of 32.26 and a Piotroski F-Score of 1.
| Altman Z-Score | 32.26 |
| Piotroski F-Score | 1 |